STOCK TITAN
  1. Home
  2. News
  3. CALC

CalciMedica Inc - CALC STOCK NEWS

Welcome to our dedicated news page for CalciMedica (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CalciMedica.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CalciMedica's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CalciMedica's position in the market.

News
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis
Rhea-AI Summary
CalciMedica Inc. announces the successful enrollment of the last patient in its Phase 2b CARPO trial of Auxora™ for acute pancreatitis. The trial reached its target enrollment of 216 patients, with topline data expected in 2Q 2024. Auxora is a small molecule inhibitor of CRAC channels developed for inflammatory and immunologic illnesses. The CEO expressed gratitude towards patients and families for their trust in the trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.61%
Tags
clinical trial
-
News
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
Rhea-AI Summary
CalciMedica Inc. reported financial results for 2023, highlighting progress in clinical trials for Auxora™ in acute pancreatitis and severe acute kidney injury. Recent achievements include IND clearance for AKI trial, expansion of AIPT study, and successful private placement financing. The company's cash position is strong, with plans to fund operations into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
earnings
-
News
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
Rhea-AI Summary
CalciMedica Inc. presented data from preclinical studies of Auxora in acute kidney injury (AKI) at the 29th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference. The results showed that Auxora improved kidney function and survival in rat models of AKI, supporting the upcoming KOURAGE trial in severe AKI patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
clinical trial
News
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
Rhea-AI Summary
CalciMedica Inc. announces positive preclinical data for Auxora in treating acute kidney injury (AKI) in rats, showing improved kidney function. The study indicates that Auxora can enhance glomerular filtration rate, suggesting potential therapeutic benefits for AKI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
clinical trial
-
News
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
Rhea-AI Summary
CalciMedica, Inc. announces the clearance of its IND application by the FDA for its lead product candidate, Auxora, to be evaluated in a Phase 2 trial for acute kidney injury with associated acute hypoxemic respiratory failure. The trial, named KOURAGE, aims to address the high mortality rate of patients suffering from severe AKI, a condition with no approved therapies. The study will evaluate 150 patients with stage 2 and 3 AKI and AHRF, with primary endpoints focusing on days alive, ventilator-free, and dialysis-free through day 30. The development of Auxora is supported by clinical and pre-clinical evidence, showing promising results in animal models of AKI and COVID-19 pneumonia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.21%
Tags
clinical trial
-
News
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
CalciMedica Inc. announced the participation of CEO Rachel Leheny in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company is focused on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses. The presentation will be available via live webcast and archived for 90 days on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.99%
Tags
conferences
News
CalciMedica Announces Private Placement of up to Approximately $55 Million
Rhea-AI Summary
CalciMedica, Inc. announced a securities purchase agreement to raise up to $55 million in gross proceeds, with an upfront funding of $20.4 million and potential additional funding of $34.2 million. The financing will support the expansion of Auxora™ clinical development, including planned Phase 2 acute kidney injury (AKI) trial, and fund subsequent clinical trials in acute pancreatitis (AP) and AKI programs. New and existing investors, including healthcare-dedicated investors, are participating in the financing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.09%
Tags
none
-
News
CalciMedica Collaborator St. Jude Children's Research Hospital Presents Data from Initial Cohort of CRSPA Study at 65th Annual ASH Meeting & Exposition
Rhea-AI Summary
CalciMedica Inc. (CALC) announced positive results from the Phase 1/2 CRSPA study of Auxora™ in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) at the 65th Annual American Society of Hematology (ASH) Meeting & Exposition. Auxora treatment potentially reduces the severity of AIPT, eliminating the need for total parenteral nutrition, and resulting in reduced hospital and intensive care unit days. The study showed a 53% reduction in days in hospital and a 40% reduction in intensive care unit days compared to a historical matched control group. None of the Auxora-treated patients had significant necrosis compared to 27% of historical control patients at 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.88%
Tags
none
-
News
CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
Rhea-AI Summary
CalciMedica Inc. (CALC) reported financial results and clinical updates for the third quarter, highlighting the expansion of Phase 1/2 CRSPA study of Auxora™ in asparaginase-induced pancreatic toxicity (AIPT) and the international expansion of Phase 2b CARPO trial in acute pancreatitis (AP) patients with accompanying systemic inflammatory response syndrome (SIRS). The company anticipates topline data from the CARPO trial in the first half of 2024 and is preparing to file an IND application for Auxora™ in acute kidney injury (AKI).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.74%
Tags
earnings
News
CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition
Rhea-AI Summary
CalciMedica Inc. announced the presentation of data from the CRSPA study of Auxora™ in asparaginase-induced pancreatic toxicity (AIPT) at the ASH Meeting. The results showed a 53% reduction in hospital days, a 40% reduction in ICU days, and eliminated the need for total parenteral nutrition (TPN).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.23%
Tags
none
Stock CALC logo
CalciMedica Inc

Nasdaq:CALC

CALC Rankings

#4644 Ranked by Market Cap
#4948 Ranked by Stock Gains
N/A Ranked by Dividends

CALC Stock Data

47.69M
4.55M
14.87%
53.08%
0.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
La Jolla

About CALC

calcimedica is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune disorders, organ transplant rejection, and other immune diseases.